Geographic Atrophy Clinical Trials

33 recruitingLast updated: May 21, 2026

There are 33 actively recruiting geographic atrophy clinical trials across 28 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4. Top locations include Dallas, Texas, United States, The Woodlands, Texas, United States, Hagerstown, Maryland, United States. Updated daily from ClinicalTrials.gov.


Geographic Atrophy Trials at a Glance

33 actively recruiting trials for geographic atrophy are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 17 trials, with the heaviest enrollment activity in Dallas, The Woodlands, and Hagerstown. Lead sponsors running geographic atrophy studies include Complement Therapeutics, Ray Therapeutics, Inc., and Regeneron Pharmaceuticals.

Browse geographic atrophy trials by phase

About Geographic Atrophy Clinical Trials

Looking for clinical trials for Geographic Atrophy? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Geographic Atrophy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Geographic Atrophy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 33 trials

Recruiting
Phase 2

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy secondary to Age Related Macular Degeneration
Novartis Pharmaceuticals272 enrolled16 locationsNCT07441642
Recruiting
Phase 2

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Geographic AtrophyMacular Degeneration
Janssen Research & Development, LLC274 enrolled104 locationsNCT06635148
Recruiting
Not Applicable

Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy

Geographic Atrophy secondary to Age Related Macular Degeneration
Okuvision GmbH70 enrolled5 locationsNCT07531927
Recruiting
Phase 3

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Age related macular degeneration (AMD)Geographic Atrophy (GA)
Regeneron Pharmaceuticals975 enrolled216 locationsNCT06541704
Recruiting
Not Applicable

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Geographic Atrophy secondary to Age Related Macular DegenerationAge-Related Macular DegenerationIntermediate AMD+1 more
i-Lumen Scientific AUS PTY LTD100 enrolled13 locationsNCT06662162
Recruiting

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

Geographic Atrophy secondary to Age Related Macular Degeneration
Complement Therapeutics75 enrolled9 locationsNCT07144137
Recruiting
Phase 1Phase 2

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

Geographic Atrophy secondary to Age Related Macular Degeneration
Complement Therapeutics75 enrolled4 locationsNCT07392255
Recruiting
Phase 1Phase 2

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy secondary to Age Related Macular Degeneration
Kriya Therapeutics, Inc.62 enrolled3 locationsNCT06765980
Recruiting

High Resolution Retinal Imaging

Geographic AtrophyAge-Related Macular DegenerationRetinitis Pigmentosa+2 more
University of Pennsylvania600 enrolled1 locationNCT01866371
Recruiting
Phase 1

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

Geographic Atrophy (GA)
Regeneron Pharmaceuticals54 enrolled5 locationsNCT07230834
Recruiting

Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study

Geographic AtrophyAge-Related Macular Degeneration
University of California, San Francisco80 enrolled1 locationNCT07556406
Recruiting

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Geographic AtrophyMacular Degeneration
Astellas Pharma Global Development, Inc.1,000 enrolled65 locationsNCT06779773
Recruiting
Phase 2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Geographic Atrophy secondary to Age Related Macular Degeneration
ADARx Pharmaceuticals, Inc.240 enrolled24 locationsNCT06990269
Recruiting
Phase 1Phase 2

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy
Sanofi104 enrolled17 locationsNCT07215234
Recruiting
Phase 2

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

Geographic Atrophy
Genentech, Inc.60 enrolled17 locationsNCT05626114
Recruiting
Phase 2

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Geographic Atrophy secondary to Age Related Macular Degeneration
Apellis Pharmaceuticals, Inc.240 enrolled43 locationsNCT07215390
Recruiting

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

X-linked RetinoschisisRetinitis PigmentosaStargardt Disease+3 more
Ray Therapeutics, Inc.25 enrolled1 locationNCT07502664
Recruiting
Phase 2

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

Geographic AtrophyDry Age-Related Macular Degeneration
Regenerative Patch Technologies, LLC24 enrolled5 locationsNCT06557460
Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Geographic Atrophy
Hoffmann-La Roche132 enrolled16 locationsNCT06961370
Recruiting
Phase 4

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Geographic AtrophyAge-Related Macular Degeneration
Astellas Pharma Inc20 enrolled16 locationsNCT06970665